| Study name |
Electronic patient self‐Reporting of Adverse‐events: Patient Information and aDvice (eRAPID): a randomised controlled trial in systemic cancer treatment |
| Methods |
Randomised trial, UK |
| Participants |
1) Adult patients (aged 18 years or over) attending St James’ Institute of Oncology, Leeds with breast cancer undertaking either neo‐adjuvant or adjuvant systemic treatment pathways, gynaecological or colorectal cancer requiring chemotherapy. 2) Prescribed at least 3 months of planned chemotherapy cycles at the time of study consent. 3) Able and willing to give informed consent. 4) Able to read and understand English. 5) Access to the Internet at home. |
| Interventions |
eRAPID (electronic patient self‐Reporting of Adverse‐events: Patient Information and aDvice) is an Internet based system for patients to self‐report symptoms and side effects (adverse events or AE) of cancer treatments. Participants (adult patients with breast cancer on neo‐adjuvant or adjuvant chemotherapy, colorectal and gynaecological cancer receiving chemotherapy) are randomised to receive the eRAPID intervention or usual care over 18 weeks of treatment. Participants in the intervention arm receive training in using the eRAPID system to provide routine weekly adverse event reports from home. Hospital staff can access eRAPID reports via the EPR and use the information during consultations or phone calls with patients. |
| Outcomes |
The primary outcome of the trial is quality of life (FACT‐G) with secondary outcomes including health economics (costs to patients and the NHS), process of care (e.g. contacts with the hospital, number of admissions, clinic appointments and changes to treatment/medications) and patient self‐efficacy. Outcome data is collected at baseline, 6, 12, 18 weeks and 12 months. The intervention is also being evaluated via end of study interviews with patient participants and clinical staff. |
| Starting date |
May 2016 |
| Contact information |
Galina Velikova, Section of Patient Centred Outcomes Research (PCOR), Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK. Email: g.velikova@leeds.ac.uk |
| Notes |
|
